Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Comprehending the inexplicable: qualitative accounts of black Caribbean and white british people severely affected by multiple sclerosis.
Vitamin A and systemic inflammation as protective factors in multiple sclerosis.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Confounding in association studies: month of birth and multiple sclerosis.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Receptos provides update on progress of lead product candidate RPC1063
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Pharmaceutical approval update.
Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.

Pages